Skip to main content
Top
Published in: Journal of Interventional Cardiac Electrophysiology 2/2022

01-03-2022 | Buprenorphine | Reviews

Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article

Authors: Farshid Etaee, Morgan Tobin, Suchith Vuppala, Alireza Komaki, Brian P. Delisle, Luigi Di Biase, John N Catanzaro, Andrea Natale, Claude S. Elayi

Published in: Journal of Interventional Cardiac Electrophysiology | Issue 2/2022

Login to get access

Abstract

Background/Purpose

Mortality associated with prescription opioids has significantly increased over the past few decades and is considered a global pandemic. Prescribed opioids can cause cardiac arrhythmias, leading to fatal outcomes and unexpected death, even in the absence of structural cardiac disease. Despite the extent of cardiac toxicity and death associated with these medications, there is limited data to suggest their influences on cardiac electrophysiology and arrhythmias, with the exception of methadone. The goal of our review is to describe the possible mechanisms and to review the different ECG changes and arrhythmias that have been reported.

Methods

A literature search was performed using Google Scholar, PubMed, Springer, Ovid, and Science Direct to identify studies that demonstrated the use of prescription opioids leading to electrocardiogram (ECG) changes and cardiac arrhythmias.

Results

Many of the commonly prescribed opioid medications can uniquely effect the ECG, and can lead to the development of various cardiac arrhythmias. One of the most significant side effects of these drugs is QTc interval prolongation, especially when administered to patients with a baseline risk for QTc prolongation. A prolonged QTc interval can cause lethal torsades de pointes and ventricular fibrillation. Obtaining an ECG at baseline, following a dosage increase, or after switching an opioid medication, is appropriate in patients taking certain prescribed opioids. Opioids are often used first line for the treatment of acute and chronic pain, procedural sedation, medication opioid use disorders, and maintenance therapy.

Conclusions

To reduce the risk of cardiac arrhythmias and to improve patient outcomes, consideration of accurate patient selection, concomitant medications, electrolyte monitoring, and vigilant ECG monitoring should be considered.
Literature
3.
go back to reference Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular complications of opioid use: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77(2):205–23.PubMedCrossRef Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular complications of opioid use: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77(2):205–23.PubMedCrossRef
5.
go back to reference Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008;121(1):66–71.PubMedPubMedCentralCrossRef Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008;121(1):66–71.PubMedPubMedCentralCrossRef
6.
go back to reference O’Connell CW, Schricker AA, Schneir AB, Metushi IG, Birgersdotter-Green U, Minns AB. High-dose loperamide abuse–associated ventricular arrhythmias. Hear Case Rep. 2016;2(3):232. O’Connell CW, Schricker AA, Schneir AB, Metushi IG, Birgersdotter-Green U, Minns AB. High-dose loperamide abuse–associated ventricular arrhythmias. Hear Case Rep. 2016;2(3):232.
7.
go back to reference Etaee F, Rezvani-Kamran A, Taheri M, Omidi G, Hasanein P, Komaki A. Comparing the antinociceptive effects of methamphetamine, buprenorphine, or both after chronic treatment and withdrawal in male rats. Basic and clinical neuroscience. 2019 Jul;10(4):313. Etaee F, Rezvani-Kamran A, Taheri M, Omidi G, Hasanein P, Komaki A. Comparing the antinociceptive effects of methamphetamine, buprenorphine, or both after chronic treatment and withdrawal in male rats. Basic and clinical neuroscience. 2019 Jul;10(4):313.
8.
go back to reference Marraffa JM, Holland MG, Sullivan RW, Morgan BW, Oakes JA, Wiegand TJ, et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol. 2014;52(9):952–7.CrossRef Marraffa JM, Holland MG, Sullivan RW, Morgan BW, Oakes JA, Wiegand TJ, et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol. 2014;52(9):952–7.CrossRef
9.
10.
go back to reference Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol. 2010;28(1):19–22.PubMedCrossRef Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol. 2010;28(1):19–22.PubMedCrossRef
11.
go back to reference Harris SC, Morganroth J, Ripa SR, Thorn MD, Colucci S. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive-and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80.PubMedCrossRef Harris SC, Morganroth J, Ripa SR, Thorn MD, Colucci S. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive-and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80.PubMedCrossRef
12.
go back to reference Shuster JP. Buprenorphine-induced hypertension and tachycardia: rare but serious. Hosp Pharm. 1996;31(1):41–2. Shuster JP. Buprenorphine-induced hypertension and tachycardia: rare but serious. Hosp Pharm. 1996;31(1):41–2.
13.
go back to reference Wolstein J, Gastpar M, Finkbeiner T, Heinrich C, Heitkamp R, Poehlke T, et al. A randomized, open-label trial comparing methadone and levo-alpha-acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry. 2009;42(01):1–8.PubMedCrossRef Wolstein J, Gastpar M, Finkbeiner T, Heinrich C, Heitkamp R, Poehlke T, et al. A randomized, open-label trial comparing methadone and levo-alpha-acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry. 2009;42(01):1–8.PubMedCrossRef
14.
go back to reference Anglin MD, Conner BT, Annon J, Longshore D. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status. Addiction. 2007;102(9):1432–42.PubMedCrossRef Anglin MD, Conner BT, Annon J, Longshore D. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status. Addiction. 2007;102(9):1432–42.PubMedCrossRef
15.
go back to reference Wieneke H, Conrads H, Wolstein J, Breuckmann F, Gastpar M, Erbel R, et al. Levo-α-acetylmethadol (LAAM) induced QTc-prolongation-results from a controlled clinical trial. Eur J Med Res. 2009;14(1):7.PubMedPubMedCentralCrossRef Wieneke H, Conrads H, Wolstein J, Breuckmann F, Gastpar M, Erbel R, et al. Levo-α-acetylmethadol (LAAM) induced QTc-prolongation-results from a controlled clinical trial. Eur J Med Res. 2009;14(1):7.PubMedPubMedCentralCrossRef
16.
go back to reference Deamer RL, Wilson DR, Clark DS, Prichard JG. Torsades de pointes associated with high dose levomethadyl acetate (Orlaam®). J Addict Dis. 2001;20(4):7–15.PubMedCrossRef Deamer RL, Wilson DR, Clark DS, Prichard JG. Torsades de pointes associated with high dose levomethadyl acetate (Orlaam®). J Addict Dis. 2001;20(4):7–15.PubMedCrossRef
17.
go back to reference Ojo A, Nag T, Iwai S, Jacobson J, Cohen M, Frenkel D. Life threatening arrhythmia induced by a common over-the-counter drug. J Am Coll Cardiol. 2018;71(11 Supplement):A2561.CrossRef Ojo A, Nag T, Iwai S, Jacobson J, Cohen M, Frenkel D. Life threatening arrhythmia induced by a common over-the-counter drug. J Am Coll Cardiol. 2018;71(11 Supplement):A2561.CrossRef
18.
go back to reference Salama A, Levin Y, Jha P, Alweis R. Ventricular fibrillation due to overdose of loperamide, the “poor man’s methadone.” J Community Hosp Intern Med Perspect. 2017;7(4):222–6.PubMedPubMedCentralCrossRef Salama A, Levin Y, Jha P, Alweis R. Ventricular fibrillation due to overdose of loperamide, the “poor man’s methadone.” J Community Hosp Intern Med Perspect. 2017;7(4):222–6.PubMedPubMedCentralCrossRef
19.
go back to reference Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic trends in loperamide abuse and misuse. Ann Emerg Med. 2017;69(1):73–8.PubMedCrossRef Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic trends in loperamide abuse and misuse. Ann Emerg Med. 2017;69(1):73–8.PubMedCrossRef
20.
go back to reference Enakpene EO, Bin Riaz I, Shirazi FM, Raz Y, Indik JH. The long QT teaser: loperamide abuse. Am J Med. 2015;128(10):1083–6.PubMedCrossRef Enakpene EO, Bin Riaz I, Shirazi FM, Raz Y, Indik JH. The long QT teaser: loperamide abuse. Am J Med. 2015;128(10):1083–6.PubMedCrossRef
21.
go back to reference Rasla S, PharmDC ASA, Garas MK, Amr El Meligy MD, Taro Minami MD. Unexpected serious cardiac arrhythmias in the setting of loperamide abuse. R I Med J. 2017;100(4):33. Rasla S, PharmDC ASA, Garas MK, Amr El Meligy MD, Taro Minami MD. Unexpected serious cardiac arrhythmias in the setting of loperamide abuse. R I Med J. 2017;100(4):33.
22.
23.
go back to reference De Vera J, Ben Kim H, Sakr AE. A case report of loperamide-induced ventricular storm. J Investig Med High Impact Case Rep. 2021;9:2324709621990768.PubMedPubMedCentral De Vera J, Ben Kim H, Sakr AE. A case report of loperamide-induced ventricular storm. J Investig Med High Impact Case Rep. 2021;9:2324709621990768.PubMedPubMedCentral
24.
go back to reference Leung G, Altshuler D, Goldenberg R, Fridman D, Yuriditsky E. Conduction disturbances and ventricular arrhythmias associated with high-dose loperamide. J Clin Toxicol. 2016;6(3):495–2161.CrossRef Leung G, Altshuler D, Goldenberg R, Fridman D, Yuriditsky E. Conduction disturbances and ventricular arrhythmias associated with high-dose loperamide. J Clin Toxicol. 2016;6(3):495–2161.CrossRef
25.
go back to reference Vaughn P, Solik MMK, Bagga S, Padanilam BJ. Electrocardiographic abnormalities, malignant ventricular arrhythmias, and cardiomyopathy associated with loperamide abuse. J Cardiovasc Electrophysiol. 2016;27(10):1230–3.PubMedCrossRef Vaughn P, Solik MMK, Bagga S, Padanilam BJ. Electrocardiographic abnormalities, malignant ventricular arrhythmias, and cardiomyopathy associated with loperamide abuse. J Cardiovasc Electrophysiol. 2016;27(10):1230–3.PubMedCrossRef
26.
go back to reference Eggleston W. Notes from the field: cardiac dysrhythmias after loperamide abuse—New York, 2008–2016. MMWR. Morbidity and mortality weekly report. 2016;65. Eggleston W. Notes from the field: cardiac dysrhythmias after loperamide abuse—New York, 2008–2016. MMWR. Morbidity and mortality weekly report. 2016;65.
27.
go back to reference Minhas AS, Schulman SP. Syncope with unusual wide complex arrhythmia in a young woman. Circulation. 2018;138(20):2289–92.PubMedCrossRef Minhas AS, Schulman SP. Syncope with unusual wide complex arrhythmia in a young woman. Circulation. 2018;138(20):2289–92.PubMedCrossRef
28.
go back to reference Rojas SF, Bonilla HG, Oglat A, Jeroudi O, Schurmann PA. Loperamide induced brugada pattern. J Am Coll Cardiol. 2018;71(11 Supplement):A2598.CrossRef Rojas SF, Bonilla HG, Oglat A, Jeroudi O, Schurmann PA. Loperamide induced brugada pattern. J Am Coll Cardiol. 2018;71(11 Supplement):A2598.CrossRef
29.
go back to reference Whittaker G, Newman J. Loperamide: an emerging drug of abuse and cause of prolonged QTc. Clin Med (Lond). 2021;21(2):150.CrossRef Whittaker G, Newman J. Loperamide: an emerging drug of abuse and cause of prolonged QTc. Clin Med (Lond). 2021;21(2):150.CrossRef
30.
go back to reference Spinner HL, Lonardo NW, Mulamalla R, Stehlik J. Ventricular tachycardia associated with high-dose chronic loperamide use. Pharmacother J Hum Pharmacol Drug Ther. 2015;35(2):234–8.CrossRef Spinner HL, Lonardo NW, Mulamalla R, Stehlik J. Ventricular tachycardia associated with high-dose chronic loperamide use. Pharmacother J Hum Pharmacol Drug Ther. 2015;35(2):234–8.CrossRef
31.
go back to reference Van Tuyl JS, Brock G, Campbell KB, Al-Khatib SM. Torsades de pointes secondary to excessive loperamide use. J Pharm Pharmacol. 2016;4:322–7. Van Tuyl JS, Brock G, Campbell KB, Al-Khatib SM. Torsades de pointes secondary to excessive loperamide use. J Pharm Pharmacol. 2016;4:322–7.
32.
go back to reference Kapaganti S, Ansari SA, Saba R, Elkhouly A, Hassib M. A Rare Case of Loperamide-Induced Cardiac Arrest. Cureus. 2020 Jul;12(7). Kapaganti S, Ansari SA, Saba R, Elkhouly A, Hassib M. A Rare Case of Loperamide-Induced Cardiac Arrest. Cureus. 2020 Jul;12(7).
33.
go back to reference Kozak PM, Harris AE, McPherson JA, Roden DM. Torsades de pointes with high-dose loperamide. J Electrocardiol. 2017;50(3):355–7.PubMedCrossRef Kozak PM, Harris AE, McPherson JA, Roden DM. Torsades de pointes with high-dose loperamide. J Electrocardiol. 2017;50(3):355–7.PubMedCrossRef
34.
go back to reference Stefek B, Wolfe LT, Cohen M. Brugada syndrome associated with adolescent loperamide abuse. Pediatrics. 2018;142(4):e20181423.PubMedCrossRef Stefek B, Wolfe LT, Cohen M. Brugada syndrome associated with adolescent loperamide abuse. Pediatrics. 2018;142(4):e20181423.PubMedCrossRef
35.
go back to reference Akel T, Bekheit S. Loperamide cardiotoxicity:“a brief review.” Ann Noninvasive Electrocardiol. 2018;23(2):e12505.PubMedCrossRef Akel T, Bekheit S. Loperamide cardiotoxicity:“a brief review.” Ann Noninvasive Electrocardiol. 2018;23(2):e12505.PubMedCrossRef
36.
go back to reference Zaman MO, Ali MU, Finkel J. A case of loperamide induced cardiac syncope. J Am Coll Cardiol. 2018;71(11 Supplement):A2550.CrossRef Zaman MO, Ali MU, Finkel J. A case of loperamide induced cardiac syncope. J Am Coll Cardiol. 2018;71(11 Supplement):A2550.CrossRef
37.
go back to reference Hughes A, Hendrickson RG, Chen BC, Valento M. Severe loperamide toxicity associated with the use of cimetidine to potentiate the “high”. The American journal of emergency medicine. 2018 Aug 1;36(8):1527-e3. Hughes A, Hendrickson RG, Chen BC, Valento M. Severe loperamide toxicity associated with the use of cimetidine to potentiate the “high”. The American journal of emergency medicine. 2018 Aug 1;36(8):1527-e3.
38.
39.
go back to reference Krantz MJ. Heterogeneous impact of methadone on the QTc interval: what are the practical implications? J Addict Dis. 2008;27(4):5–9.PubMedCrossRef Krantz MJ. Heterogeneous impact of methadone on the QTc interval: what are the practical implications? J Addict Dis. 2008;27(4):5–9.PubMedCrossRef
40.
go back to reference Alinejad S, Kazemi T, Zamani N, Hoffman RS, Mehrpour O. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577.PubMedPubMedCentral Alinejad S, Kazemi T, Zamani N, Hoffman RS, Mehrpour O. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577.PubMedPubMedCentral
41.
go back to reference Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. J Pain. 2014;15(4):338–65.PubMedCrossRef Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. J Pain. 2014;15(4):338–65.PubMedCrossRef
42.
go back to reference Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. 2015;175(3):420–7.PubMedPubMedCentralCrossRef Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. 2015;175(3):420–7.PubMedPubMedCentralCrossRef
43.
go back to reference Nash D, Okrzesik S, Scarpace Lucas S, Patel A. Methadone Use in Children: Assessment of Cardiotoxicity. Circulation. 2017 Nov 14;136(suppl_1):A17078-. Nash D, Okrzesik S, Scarpace Lucas S, Patel A. Methadone Use in Children: Assessment of Cardiotoxicity. Circulation. 2017 Nov 14;136(suppl_1):A17078-.
44.
go back to reference Ramalho D, Freitas J. Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes. Revista Portuguesa de Cardiologia. 2018 May 1;37(5):435-46. Ramalho D, Freitas J. Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes. Revista Portuguesa de Cardiologia. 2018 May 1;37(5):435-46.
45.
go back to reference Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacother J Hum Pharmacol Drug Ther. 2005;25(11):1523–9.CrossRef Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacother J Hum Pharmacol Drug Ther. 2005;25(11):1523–9.CrossRef
46.
go back to reference Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, et al. QTc interval prolongation associated with intravenous methadone. Pain. 2003;105(3):499–506.PubMedCrossRef Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, et al. QTc interval prolongation associated with intravenous methadone. Pain. 2003;105(3):499–506.PubMedCrossRef
47.
go back to reference Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93(9):1051–5.PubMedPubMedCentralCrossRef Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93(9):1051–5.PubMedPubMedCentralCrossRef
48.
go back to reference Chang K, Huang C, Liang H, Chang S, Wang Y, Liang W, et al. Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol. 2012;23(5):527–33.PubMedCrossRef Chang K, Huang C, Liang H, Chang S, Wang Y, Liang W, et al. Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol. 2012;23(5):527–33.PubMedCrossRef
49.
go back to reference Fanoe S, Jensen GB, Sjøgren P, Korsgaard MPG, Grunnet M. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol. 2009;67(2):172–9.PubMedPubMedCentralCrossRef Fanoe S, Jensen GB, Sjøgren P, Korsgaard MPG, Grunnet M. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol. 2009;67(2):172–9.PubMedPubMedCentralCrossRef
50.
go back to reference Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993–9.PubMedCrossRef Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993–9.PubMedCrossRef
51.
go back to reference Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients—a cross-sectional study. Addiction. 2007;102(2):289–300.PubMedCrossRef Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients—a cross-sectional study. Addiction. 2007;102(2):289–300.PubMedCrossRef
52.
go back to reference Chowdhury M, Wong J, Cheng A, Khilkin M, Palma E. Methadone therapy in underserved urban community: QT c prolongation and life-threatening ventricular arrhythmias. Cardiovasc Ther. 2015;33(3):127–33.PubMedCrossRef Chowdhury M, Wong J, Cheng A, Khilkin M, Palma E. Methadone therapy in underserved urban community: QT c prolongation and life-threatening ventricular arrhythmias. Cardiovasc Ther. 2015;33(3):127–33.PubMedCrossRef
53.
go back to reference Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166(12):1280–7.PubMedCrossRef Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166(12):1280–7.PubMedCrossRef
54.
go back to reference Hassamal S, Fernandez A, Rekabdarkolaee HM, Pandurangi A. QTc prolongation in veterans with heroin dependence on methadone maintenance treatment. International journal of high risk behaviors & addiction. 2015 Jun;4(2). Hassamal S, Fernandez A, Rekabdarkolaee HM, Pandurangi A. QTc prolongation in veterans with heroin dependence on methadone maintenance treatment. International journal of high risk behaviors & addiction. 2015 Jun;4(2).
55.
go back to reference Krantz MJ, Rowan SB, Mehler PS. Cocaine-related torsade de pointes in a methadone maintenance patient. J Addict Dis. 2005;24(1):53–60.PubMedCrossRef Krantz MJ, Rowan SB, Mehler PS. Cocaine-related torsade de pointes in a methadone maintenance patient. J Addict Dis. 2005;24(1):53–60.PubMedCrossRef
56.
go back to reference Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137(6):501–4.PubMedCrossRef Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137(6):501–4.PubMedCrossRef
57.
go back to reference Justo D, Gal-Oz A, Paran Y, Goldin Y, Zeltser D. Methadone-associated torsades de pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101(9):1333–8.PubMedCrossRef Justo D, Gal-Oz A, Paran Y, Goldin Y, Zeltser D. Methadone-associated torsades de pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101(9):1333–8.PubMedCrossRef
58.
go back to reference Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 2005;29(4):385–91.PubMedCrossRef Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 2005;29(4):385–91.PubMedCrossRef
59.
go back to reference Hussain T, Ewer AK. Maternal methadone may cause arrhythmias in neonates. Acta Paediatr. 2007;96(5):768–9.PubMedCrossRef Hussain T, Ewer AK. Maternal methadone may cause arrhythmias in neonates. Acta Paediatr. 2007;96(5):768–9.PubMedCrossRef
60.
go back to reference Butler B, Rubin G, Lawrance A, Batey R, Bell J. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev. 2011;30(2):173–80.PubMedCrossRef Butler B, Rubin G, Lawrance A, Batey R, Bell J. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev. 2011;30(2):173–80.PubMedCrossRef
61.
go back to reference Grodofsky S, Edson E, Huang S, Speck RM, Hatchimonji J, Lacy K, et al. The QTc effect of low-dose methadone for chronic pain: a prospective pilot study. Pain Med. 2015;16(6):1112–21.PubMedCrossRef Grodofsky S, Edson E, Huang S, Speck RM, Hatchimonji J, Lacy K, et al. The QTc effect of low-dose methadone for chronic pain: a prospective pilot study. Pain Med. 2015;16(6):1112–21.PubMedCrossRef
62.
go back to reference Mercadante S, Prestia G, Adile C, Casuccio A. Changes of QTc interval after opioid switching to oral methadone. Support Care Cancer. 2013;21(12):3421–4.PubMedCrossRef Mercadante S, Prestia G, Adile C, Casuccio A. Changes of QTc interval after opioid switching to oral methadone. Support Care Cancer. 2013;21(12):3421–4.PubMedCrossRef
63.
go back to reference Fredheim OMS, Borchgrevink PC, Hegrenæs L, Kaasa S, Dale O, Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J Pain Symptom Manage. 2006;32(2):180–5.PubMedCrossRef Fredheim OMS, Borchgrevink PC, Hegrenæs L, Kaasa S, Dale O, Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J Pain Symptom Manage. 2006;32(2):180–5.PubMedCrossRef
64.
go back to reference Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacother J Hum Pharmacol Drug Ther. 2005;25(4):611–4.CrossRef Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacother J Hum Pharmacol Drug Ther. 2005;25(4):611–4.CrossRef
65.
go back to reference Walton G, Nolan S, Sutherland C, Ahamad K. Case Report: Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest. BMJ Case Reports. 2015;2015. Walton G, Nolan S, Sutherland C, Ahamad K. Case Report: Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest. BMJ Case Reports. 2015;2015.
66.
go back to reference Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MCP. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469–75.PubMedCrossRef Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MCP. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469–75.PubMedCrossRef
67.
go back to reference Stallvik M, Nordstrand B, Kristensen Ø, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine—relation to doses and serum concentrations. Drug Alcohol Depend. 2013;129(1–2):88–93.PubMedCrossRef Stallvik M, Nordstrand B, Kristensen Ø, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine—relation to doses and serum concentrations. Drug Alcohol Depend. 2013;129(1–2):88–93.PubMedCrossRef
68.
go back to reference Athanasos P, Farquharson AL, Compton P, Psaltis P, Hay J. Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. J Addict Dis. 2008;27(3):31–5.PubMedCrossRef Athanasos P, Farquharson AL, Compton P, Psaltis P, Hay J. Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. J Addict Dis. 2008;27(3):31–5.PubMedCrossRef
69.
go back to reference Kao DP, Haigney MCP, Mehler PS, Krantz MJ. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction. 2015;110(9):1468–75.PubMedPubMedCentralCrossRef Kao DP, Haigney MCP, Mehler PS, Krantz MJ. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction. 2015;110(9):1468–75.PubMedPubMedCentralCrossRef
70.
go back to reference Sessler NE, Walker E, Chickballapur H, Kacholakalayil J, Coplan PM. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data. Postgrad Med. 2017;129(1):62–8.PubMedCrossRef Sessler NE, Walker E, Chickballapur H, Kacholakalayil J, Coplan PM. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data. Postgrad Med. 2017;129(1):62–8.PubMedCrossRef
71.
go back to reference Bohn LM, Gainetdinov RR, Lin F-T, Lefkowitz RJ, Caron MG. μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408(6813):720.PubMedCrossRef Bohn LM, Gainetdinov RR, Lin F-T, Lefkowitz RJ, Caron MG. μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408(6813):720.PubMedCrossRef
72.
go back to reference Chen S, Xiong J, Zhan Y, Liu W, Wang X. Role of different concentrations of morphine after coronary perfusion for myocardial protection. WIMJ Open. 2014;1(3):107–10.CrossRef Chen S, Xiong J, Zhan Y, Liu W, Wang X. Role of different concentrations of morphine after coronary perfusion for myocardial protection. WIMJ Open. 2014;1(3):107–10.CrossRef
73.
go back to reference Skrabalova J, Neckar J, Hejnova L, Bartonova I, Kolar F, Novotny J. Antiarrhythmic effect of prolonged morphine exposure is accompanied by altered myocardial adenylyl cyclase signaling in rats. Pharmacol Rep. 2012;64(2):351–9.PubMedCrossRef Skrabalova J, Neckar J, Hejnova L, Bartonova I, Kolar F, Novotny J. Antiarrhythmic effect of prolonged morphine exposure is accompanied by altered myocardial adenylyl cyclase signaling in rats. Pharmacol Rep. 2012;64(2):351–9.PubMedCrossRef
74.
go back to reference Lee CW, Muo CH, Liang JA, Lin MC, Kao CH. Atrial fibrillation is associated with morphine treatment in female breast cancer patients: a retrospective population-based time-dependent cohort study. Medicine. 2016 Mar;95(11). Lee CW, Muo CH, Liang JA, Lin MC, Kao CH. Atrial fibrillation is associated with morphine treatment in female breast cancer patients: a retrospective population-based time-dependent cohort study. Medicine. 2016 Mar;95(11).
75.
go back to reference Vincenzo Z, Alphonse S, Matteo P, Lorenzo S, Riccardo C, Pietro G, et al. Morphine-induced supraventricular tachycardia in near-term fetus. Ital J Pediatr. 2018;44(1):111.PubMedCentralCrossRef Vincenzo Z, Alphonse S, Matteo P, Lorenzo S, Riccardo C, Pietro G, et al. Morphine-induced supraventricular tachycardia in near-term fetus. Ital J Pediatr. 2018;44(1):111.PubMedCentralCrossRef
76.
77.
go back to reference Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, et al. Effect and safety of morphine use in acute anterior ST-segment elevation myocardial infarction. J Am Heart Assoc. 2018;7(4):e006833.PubMedPubMedCentralCrossRef Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, et al. Effect and safety of morphine use in acute anterior ST-segment elevation myocardial infarction. J Am Heart Assoc. 2018;7(4):e006833.PubMedPubMedCentralCrossRef
78.
go back to reference Baranchuk A, Simpson CS, Methot M, Gibson K, Strum D. Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Can J Cardiol. 2008;24(7):S38-40.CrossRef Baranchuk A, Simpson CS, Methot M, Gibson K, Strum D. Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Can J Cardiol. 2008;24(7):S38-40.CrossRef
79.
go back to reference Beheshti A, Lucas L, Dunz T, Haydash M, Chiodi H, Edmiston B, et al. An evaluation of naloxone use for opioid overdoses in West Virginia: a literature review. Am Med J. 2015;6(1):9.PubMedPubMedCentral Beheshti A, Lucas L, Dunz T, Haydash M, Chiodi H, Edmiston B, et al. An evaluation of naloxone use for opioid overdoses in West Virginia: a literature review. Am Med J. 2015;6(1):9.PubMedPubMedCentral
80.
go back to reference Deshpande G, Gill A. Cardiac arrest following naloxone in an extremely preterm neonate. Eur J Pediatr. 2009;168(1):115.PubMedCrossRef Deshpande G, Gill A. Cardiac arrest following naloxone in an extremely preterm neonate. Eur J Pediatr. 2009;168(1):115.PubMedCrossRef
81.
go back to reference Sarne Y, Hochman I, Eshed M, Oppenheimer E. Antiarrhythmic action of naloxone: direct, non-opiate effect on the rat heart. Life Sci. 1988;43(10):859–64.PubMedCrossRef Sarne Y, Hochman I, Eshed M, Oppenheimer E. Antiarrhythmic action of naloxone: direct, non-opiate effect on the rat heart. Life Sci. 1988;43(10):859–64.PubMedCrossRef
82.
go back to reference Lameijer H, Azizi N, Ligtenberg JJM, Ter Maaten JC. Ventricular tachycardia after naloxone administration: a drug related complication? Case report and literature review. Drug Saf Case Rep. 2014;1(1):2.PubMedPubMedCentralCrossRef Lameijer H, Azizi N, Ligtenberg JJM, Ter Maaten JC. Ventricular tachycardia after naloxone administration: a drug related complication? Case report and literature review. Drug Saf Case Rep. 2014;1(1):2.PubMedPubMedCentralCrossRef
83.
go back to reference Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine–naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88(1):75–8.PubMedCrossRef Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine–naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88(1):75–8.PubMedCrossRef
84.
go back to reference Kazbour H, Harrison J, Brown S, Yanowitz F, Snow G, McDonald A, et al. Does buprenorphine/naloxone therapy prolong ventricular repolarization during sleep? Chest. 2014;146(4):955A.CrossRef Kazbour H, Harrison J, Brown S, Yanowitz F, Snow G, McDonald A, et al. Does buprenorphine/naloxone therapy prolong ventricular repolarization during sleep? Chest. 2014;146(4):955A.CrossRef
86.
go back to reference Baker JR, Best AIM, Pade PA, McCance-Katz EF. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006;40(3):392–6.PubMedCrossRef Baker JR, Best AIM, Pade PA, McCance-Katz EF. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006;40(3):392–6.PubMedCrossRef
87.
go back to reference Poole SA, Pecoraro A, Subramaniam G, Woody G, Vetter VL. The presence or absence of QTc prolongation in buprenorphine-naloxone among youth with opioid dependence. J Addict Med. 2016;10(1):26.PubMedPubMedCentralCrossRef Poole SA, Pecoraro A, Subramaniam G, Woody G, Vetter VL. The presence or absence of QTc prolongation in buprenorphine-naloxone among youth with opioid dependence. J Addict Med. 2016;10(1):26.PubMedPubMedCentralCrossRef
88.
go back to reference Dadpour B, Gholoobi A, Tajoddini S, Habibi A. Acute myocardial infarction following naltrexone consumption; a case report. Emergency. 2017;5(1). Dadpour B, Gholoobi A, Tajoddini S, Habibi A. Acute myocardial infarction following naltrexone consumption; a case report. Emergency. 2017;5(1).
89.
go back to reference Herman BH, Asleson GS, Powell A, Borghese IF, Ruckman R, Fitzgerald C. Cardiovascular and other physical effects of acute administration of naltrexone in autistic children. J Child Adolesc Psychopharmacol. 1993;3(3):157–68.PubMedCrossRef Herman BH, Asleson GS, Powell A, Borghese IF, Ruckman R, Fitzgerald C. Cardiovascular and other physical effects of acute administration of naltrexone in autistic children. J Child Adolesc Psychopharmacol. 1993;3(3):157–68.PubMedCrossRef
91.
go back to reference Meents JE, Juhasz K, Stölzle‐Feix S, Peuckmann‐Post V, Rolke R, Lampert A. The opioid oxycodone use‐dependently inhibits the cardiac sodium channel NaV1. 5. British journal of pharmacology. 2018 Jul;175(14):3007-20. Meents JE, Juhasz K, Stölzle‐Feix S, Peuckmann‐Post V, Rolke R, Lampert A. The opioid oxycodone use‐dependently inhibits the cardiac sodium channel NaV1. 5. British journal of pharmacology. 2018 Jul;175(14):3007-20.
92.
go back to reference Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer. 2003;11(2):84–92.PubMedCrossRef Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer. 2003;11(2):84–92.PubMedCrossRef
93.
go back to reference Syed IA, Kuzel AR, Lodhi MU, Chowdhury W, Rahim U, Rahim M. Persistent Bradycardia with the Long-term Use of Phenytoin and Oxycodone: First Case Report. Cureus. 2018 Feb;10(2). Syed IA, Kuzel AR, Lodhi MU, Chowdhury W, Rahim U, Rahim M. Persistent Bradycardia with the Long-term Use of Phenytoin and Oxycodone: First Case Report. Cureus. 2018 Feb;10(2).
94.
go back to reference Berling I, Whyte IM, Isbister GK. Oxycodone overdose causes naloxone responsive coma and QT prolongation. QJM An Int J Med. 2012;106(1):35–41.CrossRef Berling I, Whyte IM, Isbister GK. Oxycodone overdose causes naloxone responsive coma and QT prolongation. QJM An Int J Med. 2012;106(1):35–41.CrossRef
95.
go back to reference Daniell HW. Torsades-de-pointes associated with Taku-Tsubo cardiomyopathy following greatly reduced oxycodone use in an elderly woman. J Opioid Manag. 2011;7(2):155–9.PubMedCrossRef Daniell HW. Torsades-de-pointes associated with Taku-Tsubo cardiomyopathy following greatly reduced oxycodone use in an elderly woman. J Opioid Manag. 2011;7(2):155–9.PubMedCrossRef
96.
go back to reference Song MK, Bae EJ, Baek JS, Kwon BS, Kim GB, Il Noh C, et al. QT prolongation and life threatening ventricular tachycardia in a patient injected with intravenous meperidine (Demerol®). Korean Circ J. 2011;41(6):342–5.PubMedPubMedCentralCrossRef Song MK, Bae EJ, Baek JS, Kwon BS, Kim GB, Il Noh C, et al. QT prolongation and life threatening ventricular tachycardia in a patient injected with intravenous meperidine (Demerol®). Korean Circ J. 2011;41(6):342–5.PubMedPubMedCentralCrossRef
97.
go back to reference Keller GA, Villa Etchegoyen MC, Fernandez N, Olivera NM, Quiroga PN, Diez RA. Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations. Int J Clin Pharmacol Ther. 2017;55:275–85.PubMedCrossRef Keller GA, Villa Etchegoyen MC, Fernandez N, Olivera NM, Quiroga PN, Diez RA. Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations. Int J Clin Pharmacol Ther. 2017;55:275–85.PubMedCrossRef
98.
go back to reference Chakravarthy M, Reddy K, Kavarganahalli D, Rajathadri S, Devanahalli A. Complete heart block after administration of intravenous pethidine. Karnataka Anaesth J. 2015;1(1):31.CrossRef Chakravarthy M, Reddy K, Kavarganahalli D, Rajathadri S, Devanahalli A. Complete heart block after administration of intravenous pethidine. Karnataka Anaesth J. 2015;1(1):31.CrossRef
99.
go back to reference Cole JB, Sattiraju S, Bilden EF, Asinger RW, Bertog SC. Isolated tramadol overdose associated with Brugada ECG pattern. Pacing Clin Electrophysiol. 2012;35(8):e219–21.PubMedCrossRef Cole JB, Sattiraju S, Bilden EF, Asinger RW, Bertog SC. Isolated tramadol overdose associated with Brugada ECG pattern. Pacing Clin Electrophysiol. 2012;35(8):e219–21.PubMedCrossRef
100.
go back to reference Mehrpour O, Sharifi M, Zamani N. Tramadol poisoning. Toxicology Studies: Cells, Drugs and Environment. 2015 Jul 8;101. Mehrpour O, Sharifi M, Zamani N. Tramadol poisoning. Toxicology Studies: Cells, Drugs and Environment. 2015 Jul 8;101.
101.
go back to reference Keller GA, Etchegoyen MCV, Fernandez N, Olivera NM, Quiroga PN, Belloso WH, et al. Tramadol induced QTc-interval prolongation: prevalence, clinical factors and correlation to plasma concentrations. Curr Drug Saf. 2016;11(3):206–14.PubMedCrossRef Keller GA, Etchegoyen MCV, Fernandez N, Olivera NM, Quiroga PN, Belloso WH, et al. Tramadol induced QTc-interval prolongation: prevalence, clinical factors and correlation to plasma concentrations. Curr Drug Saf. 2016;11(3):206–14.PubMedCrossRef
102.
go back to reference Emamhadi M, Sanaei-Zadeh H, Nikniya M, Zamani N, Dart RC. Electrocardiographic manifestations of tramadol toxicity with special reference to their ability for prediction of seizures. Am J Emerg Med. 2012;30(8):1481–5.PubMedCrossRef Emamhadi M, Sanaei-Zadeh H, Nikniya M, Zamani N, Dart RC. Electrocardiographic manifestations of tramadol toxicity with special reference to their ability for prediction of seizures. Am J Emerg Med. 2012;30(8):1481–5.PubMedCrossRef
103.
go back to reference Samanta S, Samanta S, Chatterjee D, Soni KD. Cardiac arrest after tramadol injection in a polytrauma patient. J Anaesthesiol Clin Pharmacol. 2016;32(4):539.PubMedPubMedCentralCrossRef Samanta S, Samanta S, Chatterjee D, Soni KD. Cardiac arrest after tramadol injection in a polytrauma patient. J Anaesthesiol Clin Pharmacol. 2016;32(4):539.PubMedPubMedCentralCrossRef
104.
go back to reference Ghamsari AA, Dadpour B, Najari F. Frequency of electrocardiographic abnormalities in tramadol poisoned patients; a brief report. Emergency. 2016;4(3):151. Ghamsari AA, Dadpour B, Najari F. Frequency of electrocardiographic abnormalities in tramadol poisoned patients; a brief report. Emergency. 2016;4(3):151.
105.
go back to reference Massarella J, Ariyawansa J, Natarajan J, Francke S, Murtaugh T, DeLemos B, Vaughan S, Fonseca S. Tramadol hydrochloride at steady state lacks clinically relevant QTc interval increases in healthy adults. Clinical pharmacology in drug development. 2019 Jan;8(1):95-106. Massarella J, Ariyawansa J, Natarajan J, Francke S, Murtaugh T, DeLemos B, Vaughan S, Fonseca S. Tramadol hydrochloride at steady state lacks clinically relevant QTc interval increases in healthy adults. Clinical pharmacology in drug development. 2019 Jan;8(1):95-106.
106.
107.
go back to reference Moghadam PH, Zarei N, Farsi D, Abbasi S, Mofidi M, Rezai M, et al. Electrocardiographic changes in patients with tramadol-induced idiosyncratic seizures. Turk J Emerg Med. 2016;16(4):151–4.CrossRef Moghadam PH, Zarei N, Farsi D, Abbasi S, Mofidi M, Rezai M, et al. Electrocardiographic changes in patients with tramadol-induced idiosyncratic seizures. Turk J Emerg Med. 2016;16(4):151–4.CrossRef
108.
109.
go back to reference Chang DJ, Kweon TD, Nam SB, Lee JS, Shin CS, Park CH, et al. Effects of fentanyl pretreatment on the QTc interval during propofol induction. Anaesthesia. 2008;63(10):1056–60.PubMedCrossRef Chang DJ, Kweon TD, Nam SB, Lee JS, Shin CS, Park CH, et al. Effects of fentanyl pretreatment on the QTc interval during propofol induction. Anaesthesia. 2008;63(10):1056–60.PubMedCrossRef
110.
go back to reference Hancı V, Yurtlu S, Karabağ T, Okyay D, Hakimoğlu S, Kayhan G, et al. Effects of esmolol, lidocaine and fentanyl on P wave dispersion, QT, QTc intervals and hemodynamic responses to endotracheal intubation during propofol induction: a comparative study. Braz J Anesthesiol. 2013;63(3):235–44.PubMedCrossRef Hancı V, Yurtlu S, Karabağ T, Okyay D, Hakimoğlu S, Kayhan G, et al. Effects of esmolol, lidocaine and fentanyl on P wave dispersion, QT, QTc intervals and hemodynamic responses to endotracheal intubation during propofol induction: a comparative study. Braz J Anesthesiol. 2013;63(3):235–44.PubMedCrossRef
111.
go back to reference Wilton NCT, Hantler CB. Congenital long QT syndrome: changes in QT interval during anesthesia with thiopental, vecuronium, fentanyl, and isoflurane. Anesth Analg. 1987;66(4):357–60.PubMedCrossRef Wilton NCT, Hantler CB. Congenital long QT syndrome: changes in QT interval during anesthesia with thiopental, vecuronium, fentanyl, and isoflurane. Anesth Analg. 1987;66(4):357–60.PubMedCrossRef
112.
go back to reference Lischke V, Wilke H, Probst S, Behne M, Kessler P. Prolongation of the QT–interval during induction of anesthesia in patients with coronary artery disease. Acta Anaesthesiol Scand. 1994;38(2):144–8.PubMedCrossRef Lischke V, Wilke H, Probst S, Behne M, Kessler P. Prolongation of the QT–interval during induction of anesthesia in patients with coronary artery disease. Acta Anaesthesiol Scand. 1994;38(2):144–8.PubMedCrossRef
113.
go back to reference Cho JS, Kim SH, Shin S, Pak H-N, Yang SJ, Oh YJ. Effects of dexmedetomidine on changes in heart rate variability and hemodynamics during tracheal intubation. Am J Ther. 2016;23(2):e369–76.PubMedCrossRef Cho JS, Kim SH, Shin S, Pak H-N, Yang SJ, Oh YJ. Effects of dexmedetomidine on changes in heart rate variability and hemodynamics during tracheal intubation. Am J Ther. 2016;23(2):e369–76.PubMedCrossRef
114.
go back to reference Fareed A, Vayalapalli S, Scheinberg K, Gale R, Casarella J, Drexler K. QTc interval prolongation for patients in methadone maintenance treatment: a five years follow-up study. Am J Drug Alcohol Abuse. 2013;39:235–40.PubMedCrossRef Fareed A, Vayalapalli S, Scheinberg K, Gale R, Casarella J, Drexler K. QTc interval prolongation for patients in methadone maintenance treatment: a five years follow-up study. Am J Drug Alcohol Abuse. 2013;39:235–40.PubMedCrossRef
Metadata
Title
Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article
Authors
Farshid Etaee
Morgan Tobin
Suchith Vuppala
Alireza Komaki
Brian P. Delisle
Luigi Di Biase
John N Catanzaro
Andrea Natale
Claude S. Elayi
Publication date
01-03-2022
Publisher
Springer US
Published in
Journal of Interventional Cardiac Electrophysiology / Issue 2/2022
Print ISSN: 1383-875X
Electronic ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-021-01072-1

Other articles of this Issue 2/2022

Journal of Interventional Cardiac Electrophysiology 2/2022 Go to the issue